Retrophin Reports First Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Retrophin Reports First Quarter 2019 Financial Results

Retrophin (RTRX) Misses Q1 EPS by 6c, Revenues Miss

May 7, 2019 4:37 PM EDT

Retrophin (NASDAQ: RTRX) reported Q1 EPS of ($0.63), $0.06 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $39.57 million versus the consensus estimate of $41 million.

Top-line data from the pivotal Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase-associated neurodegeneration (PKAN) are anticipated in the third quarter of 2019, followed by anticipated submissions for a New Drug Application (NDA) in the U.S. and Marketing Authorization Application (MAA) in the EU in 2020The Company expects to make a... More